PDGFRA immunostaining can help in the diagnosis of gastrointestinal stromal tumors

Francesca Miselli, Clara Millefanti, Elena Conca, Tiziana Negri, Cristina Piacenza, Marco A. Pierotti, Elena Tamborini, Silvana Pilotti

Research output: Contribution to journalArticle

Abstract

Gastrointestinal stromal tumors (GISTs) are characterized by the presence of activating mutations affecting the c-Kit or the PDGFRA gene. Although these mutations are mutually exclusive, their proteins are coexpressed in many GISTs with various modulations of immunostaining depending on which gene is mutated. CD117 expression is currently considered a sensitive (although not entirely specific) marker of KIT activation, but there is no consensus concerning the reliability of PDGFRA antibody. Our database contains 236 molecularly analyzed GISTs, and we here describe the 180 cases that underwent KIT/PDGFRA immunophenotyping. By correlating the immunophenotype with the molecular status of the genes expected to be involved, we observed the coexpression of KIT and PDGFRA in the majority of the mutated c-Kit and wild-type c-Kit/PDGFRA GISTs, whereas the -/+ immunophenotype (0% vs. 48.6%) and PDGFRA dotlike immunostaining (P

Original languageEnglish
Pages (from-to)738-743
Number of pages6
JournalAmerican Journal of Surgical Pathology
Volume32
Issue number5
DOIs
Publication statusPublished - May 2008

Fingerprint

Gastrointestinal Stromal Tumors
Genes
Immunophenotyping
Mutation
Databases
Antibodies
Proteins

Keywords

  • Dotlike decoration
  • GIST
  • Immunohistochemistry
  • Molecular analyses
  • PDGFRA

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine

Cite this

Miselli, F., Millefanti, C., Conca, E., Negri, T., Piacenza, C., Pierotti, M. A., ... Pilotti, S. (2008). PDGFRA immunostaining can help in the diagnosis of gastrointestinal stromal tumors. American Journal of Surgical Pathology, 32(5), 738-743. https://doi.org/10.1097/PAS.0b013e31815c47e8

PDGFRA immunostaining can help in the diagnosis of gastrointestinal stromal tumors. / Miselli, Francesca; Millefanti, Clara; Conca, Elena; Negri, Tiziana; Piacenza, Cristina; Pierotti, Marco A.; Tamborini, Elena; Pilotti, Silvana.

In: American Journal of Surgical Pathology, Vol. 32, No. 5, 05.2008, p. 738-743.

Research output: Contribution to journalArticle

Miselli, F, Millefanti, C, Conca, E, Negri, T, Piacenza, C, Pierotti, MA, Tamborini, E & Pilotti, S 2008, 'PDGFRA immunostaining can help in the diagnosis of gastrointestinal stromal tumors', American Journal of Surgical Pathology, vol. 32, no. 5, pp. 738-743. https://doi.org/10.1097/PAS.0b013e31815c47e8
Miselli, Francesca ; Millefanti, Clara ; Conca, Elena ; Negri, Tiziana ; Piacenza, Cristina ; Pierotti, Marco A. ; Tamborini, Elena ; Pilotti, Silvana. / PDGFRA immunostaining can help in the diagnosis of gastrointestinal stromal tumors. In: American Journal of Surgical Pathology. 2008 ; Vol. 32, No. 5. pp. 738-743.
@article{2627a77b0c46440db95cc8bc6d36bdea,
title = "PDGFRA immunostaining can help in the diagnosis of gastrointestinal stromal tumors",
abstract = "Gastrointestinal stromal tumors (GISTs) are characterized by the presence of activating mutations affecting the c-Kit or the PDGFRA gene. Although these mutations are mutually exclusive, their proteins are coexpressed in many GISTs with various modulations of immunostaining depending on which gene is mutated. CD117 expression is currently considered a sensitive (although not entirely specific) marker of KIT activation, but there is no consensus concerning the reliability of PDGFRA antibody. Our database contains 236 molecularly analyzed GISTs, and we here describe the 180 cases that underwent KIT/PDGFRA immunophenotyping. By correlating the immunophenotype with the molecular status of the genes expected to be involved, we observed the coexpression of KIT and PDGFRA in the majority of the mutated c-Kit and wild-type c-Kit/PDGFRA GISTs, whereas the -/+ immunophenotype (0{\%} vs. 48.6{\%}) and PDGFRA dotlike immunostaining (P",
keywords = "Dotlike decoration, GIST, Immunohistochemistry, Molecular analyses, PDGFRA",
author = "Francesca Miselli and Clara Millefanti and Elena Conca and Tiziana Negri and Cristina Piacenza and Pierotti, {Marco A.} and Elena Tamborini and Silvana Pilotti",
year = "2008",
month = "5",
doi = "10.1097/PAS.0b013e31815c47e8",
language = "English",
volume = "32",
pages = "738--743",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - PDGFRA immunostaining can help in the diagnosis of gastrointestinal stromal tumors

AU - Miselli, Francesca

AU - Millefanti, Clara

AU - Conca, Elena

AU - Negri, Tiziana

AU - Piacenza, Cristina

AU - Pierotti, Marco A.

AU - Tamborini, Elena

AU - Pilotti, Silvana

PY - 2008/5

Y1 - 2008/5

N2 - Gastrointestinal stromal tumors (GISTs) are characterized by the presence of activating mutations affecting the c-Kit or the PDGFRA gene. Although these mutations are mutually exclusive, their proteins are coexpressed in many GISTs with various modulations of immunostaining depending on which gene is mutated. CD117 expression is currently considered a sensitive (although not entirely specific) marker of KIT activation, but there is no consensus concerning the reliability of PDGFRA antibody. Our database contains 236 molecularly analyzed GISTs, and we here describe the 180 cases that underwent KIT/PDGFRA immunophenotyping. By correlating the immunophenotype with the molecular status of the genes expected to be involved, we observed the coexpression of KIT and PDGFRA in the majority of the mutated c-Kit and wild-type c-Kit/PDGFRA GISTs, whereas the -/+ immunophenotype (0% vs. 48.6%) and PDGFRA dotlike immunostaining (P

AB - Gastrointestinal stromal tumors (GISTs) are characterized by the presence of activating mutations affecting the c-Kit or the PDGFRA gene. Although these mutations are mutually exclusive, their proteins are coexpressed in many GISTs with various modulations of immunostaining depending on which gene is mutated. CD117 expression is currently considered a sensitive (although not entirely specific) marker of KIT activation, but there is no consensus concerning the reliability of PDGFRA antibody. Our database contains 236 molecularly analyzed GISTs, and we here describe the 180 cases that underwent KIT/PDGFRA immunophenotyping. By correlating the immunophenotype with the molecular status of the genes expected to be involved, we observed the coexpression of KIT and PDGFRA in the majority of the mutated c-Kit and wild-type c-Kit/PDGFRA GISTs, whereas the -/+ immunophenotype (0% vs. 48.6%) and PDGFRA dotlike immunostaining (P

KW - Dotlike decoration

KW - GIST

KW - Immunohistochemistry

KW - Molecular analyses

KW - PDGFRA

UR - http://www.scopus.com/inward/record.url?scp=42649117800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42649117800&partnerID=8YFLogxK

U2 - 10.1097/PAS.0b013e31815c47e8

DO - 10.1097/PAS.0b013e31815c47e8

M3 - Article

C2 - 18360281

AN - SCOPUS:42649117800

VL - 32

SP - 738

EP - 743

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 5

ER -